Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1117-1119. doi: 10.19723/j.issn.1671-167X.2018.06.032

• Article • Previous Articles     Next Articles

A case of gout secondary to primary myelofibrosis

Lan-lan JI,Yan-jie HAO,Zhuo-li ZHANG()   

  1. Department of Rheumatology and Immunology,Peking University First Hospital, Beijing 100034, China
  • Received:2018-07-09 Online:2018-12-18 Published:2018-12-18
  • Contact: Zhuo-li ZHANG E-mail:zhuoli.zhang@126.com

RICH HTML

  

Abstract:

A 52-year-old man was referred to our department with a 2-year history of polyarthritis. He was diagnosed as gout due to acute arthritis of bilateral feet dorsum 2 years ago,but he didn’t receive any standard treatment. 1 year ago,there were more and more joints evolved during the gout attack,and many subcutaneous nodules occurred. When he presented to our clinic 1 month ago,the urate acid level was as high as 715 μmol/L. Moreover,we could find bone erosion in the X rays of his hand and foot,as well as synovitis,double contour sign and tophus on the ultrasound examination. The diagnosis of gout was clearly and definitely. However,he had leukocytosis and thrombocytosis for 4 years in the past history,and the urate acid level was only 400 μmol/L at that time. He also had well-controlled hypertension. The family history was unremarkable. Furthermore,we found megalosplenia on his physical examination. The bone marrow examination showed myelofibrosis and JAK2 V617F gene was positive. He was diagnosed as primary myelofibrosis and treated with interferon-α,together with urate acid-lowing therapy (febuxostat 60 mg once daily). Following-up for 1 year,the dosage of febuxostat decreased to 40 mg once daily,and the patient didn’t have gout attack again,some of the tophus diminished,and the urate acid level ranged from 400 to 500 μmol/L. Gout is a common disease in clinical practice,usually combined with metabolic syndrome,chronic renal failure and specific drugs using (diuretic and calcineurin inhibitors). However,it is relatively rare to see gout associated with myeloproliferative diseases,including polycythemia vera,primary thrombocythemia,primary myelofibrosis and chronic myelocytic leukemia.In these diseases,the turnover of nucleic acids is greatly augmented,and an excess of purine metabolites,including uric acid,is released. In the natural course of gout,the appearance of tophus from the first onset of arthritis usually takes several years. This patient only had one traditional risk factor,but his urate acid level was remarkably high and he developed tophus in a short term. After treatment of primary myelofibrosis,the symptom of gout partially alleviated. Careful physical examination and medical history taking lead to the diagnosis of secondary gout,which should be reminded in the daily practice.

Key words: Secondary gout, Tophus, Primary myelofibrosis, Myeloproliferative diseases

CLC Number: 

  • R593

Figure 1

The X-ray of bilateral wrists,hands (A) and feet (B),the arrows show the bone erosion"

Figure 2

The double contour sign of left talus. We can see the double contour sign of talus in the transverse scan (arrow)"

Figure 3

Tophus of right foot,there was a mass with low-high mixed echo above the talonavicular joint,with clear bound line and spotted Doppler signal (arrow)"

[1] 中华医学会风湿病学分会. 2016中国痛风诊疗指南[J]. 中华内科杂志, 2016,55(11):892-899.
[2] Neogi T, Jansen TLTA, Dalbeth N , et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1789-1798.
doi: 10.1136/annrheumdis-2015-208237 pmid: 4602275
[3] Yü TF . Secondary gout associated with myeloproliferative diseases[J]. Arthritis Rheum, 1965,8(5):765-771.
doi: 10.1002/art.1780080439 pmid: 5216775
[4] Gutman AB . The past four decades of progress in the knowledge of gout, with an assessment of the present status[J]. Arthritis Rheum, 1973,16(4):431-445.
doi: 10.1002/(ISSN)1529-0131
[5] Takahashi H, Hattori A, Shibata A . Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders[J]. Tohoku J Exp Med, 1982,138(1):71-80.
doi: 10.1620/tjem.138.71 pmid: 6959382
[6] Barbui T, Carobbio A, Cervantes F , et al. Thrombosis in primary myelofibrosis: incidence and risk factors[J]. Blood, 2010,115(4):778-782.
doi: 10.1182/blood-2009-08-238956 pmid: 19965680
[7] Liu TT, Chen JB, Chen WJ , et al. Idiopathic myelofibrosis associated with renal extramedullary hematopoiesis and nephrotic syndrome: case report[J]. Chang Gung Med J, 2000,23(3):169-174.
pmid: 15641221
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Jiyan CHU, Ping LI, Jing TIAN, Diyu FU, Lin GUO, Rui SUN, Yadi LI. Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 175-183.
[3] Yuan LIU, Guixiu SHI. Change from Sjögren syndrome to Sjögren disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1015-1017.
[4] Yirui LIAN, Jingxuan LIU, Liang ZHAO, Jing ZHAO, Sitian ZANG, Yuhui LI. Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1018-1023.
[5] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[6] Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041.
[7] Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[8] Yayun ZHAO, Mengfan NI, Xue LI, Bei WANG, Gong CHENG, Jing HE, Yuebo JIN. Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1051-1060.
[9] Jiajing PENG, Li CUI. Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1061-1066.
[10] Yajing GAO, Zhengfang LI, Mengsi MA, Lijun WU. Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1067-1073.
[11] Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[12] Xinfeng WU, Siliang MAN, Dazhao CHEN, Yong HUA, Xijie WEN, Yingyue DING, Liang ZHANG, Xiujuan HOU. A long-term review for radiographic parameters of hips in axial spondyloarthritis patients with end-stage hip involvement: A 24-year trend analysis from a single high-volume tertiary center [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1089-1095.
[13] Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106.
[14] Yanyan LI, Xiangjun LIU, Gongming LI, Chun LI, Yuan JIA. Clinic behavior and therapeutic status of patients with antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1107-1112.
[15] Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!